FDA approves Combigan

Article

The FDA has approved Allergan's Combigan for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

The FDA has approved Allergan's Combigan for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

Combigan (brimonidine tartrate/timolol maleate) ophthalmic solution is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor. In pivotal 12-month trials, the drug significantly reduced mean IOP by up to 7.6 mmHg from baseline and was found to be well tolerated.

Related Videos
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
Dr Mary Elizabeth Hartnett speaks with David Hutton of Ophthalmology Times
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
Dr Ali Erginay discusses his EURETINA presentation
© 2023 MJH Life Sciences

All rights reserved.